Header Logo

Connection

CARLOS CAULIN to Cetuximab

Back to Details
This is a "connection" page, showing publications CARLOS CAULIN has written about Cetuximab.
CARLOS CAULIN
Connection Strength
0.049
Cetuximab
  1. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol. 2023 08 01; 41(22):3851-3862.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.